Compare Enbridge Inc (ENB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Enbridge Inc trades at $46.55 (market cap $102.60B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Enbridge Inc pays a 6.1% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ENB | VRTX | |
|---|---|---|
Market Cap | $102.60B | $128.16B |
Volume | 3,673,079 | 806,603 |
Sector | Energy | Health |
52-Week High | $58.04 | $557.96 |
52-Week Low | $45.23 | $407.37 |
Typical Hold Time | 91 Days | 120 Days |
Enterprise Value | $184.87B | $122.29B |
Dividend Yield | 6.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $46.54, showing no change in the latest session. The stock exhibits a bearish technical signal with strong selling pressure on moving averages, though RSI levels suggest potential oversold conditions. Fundamentally, the company reported revenue of $65.19 billion in 2025 with a net income margin of 7.34%, while consistently beating EPS estimates in recent quarters. A dividend of $0.97 per share is scheduled for payment on September 1, 2026.
The outlook for ENB is mixed; analyst consensus is a 'Buy' with a price target of $61.63, implying significant upside, but technical indicators and rising debt-to-asset ratios pose risks. Investment opportunity lies in its stable cash flows and dividend yield, while key risks include interest rate sensitivity and execution of its $41 billion project backlog.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
